Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2467${count})

  • Rapid Response Innovation Awards, 2010
    SNCA Haplotyping in Parkinson's Disease and Multiple System Atrophy

    Objective/Rationale:
    A succinct, lay-oriented statement of the scientific rationale for this project. We have recently shown that genetic variants at the SNCA gene locus, coding for the alpha-synuclein...

  • Rapid Response Innovation Awards, 2010
    Resting State fMRI as a Biomarker for Parkinson's Disease

    Objective/Rationale
    There is an increasingly interest in finding biomarkers that can objectively evaluate the disease progression and the effects of neuroprotective treatment on the course of...

  • MJFF Research Grant, 2010
    Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism

    Objective/Rationale
    Transgenic pre-clinical models are instrumental to investigate mutation-induced abnormalities at the bio-chemical, cellular level in a manner not possible in humans. In humans...

  • Therapeutics Development Initiative, 2010
    Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    Objective/Rationale
    Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and...

  • Therapeutics Development Initiative, 2010
    HE3286 as Treatment for Parkinson's Disease

    Objective/Rationale
    Dehydroepiandrosterone (DHEA), a common neutraceutical and potent neuro-steroid has been suggested as a neuroprotective treatment for Parkinson’s disease (PD). However, DHEA is...

  • Therapeutics Development Initiative, 2010
    Evaluation of the Neuroprotectivity Ability of Zymes' Water-soluble CoQ10 (WS-CoQ10) in Pre-clinical Models of PD; Preclinical Validation and Dose Optimization for Clinical Study

    Objective/Rationale:
    Coenzyme Q10 is a lipid soluble naturally occurring compound essential for energy production and defence against oxidative stress.  Recent clinical studies indicate that it may...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.